Drugs / Lactiplantibacillus plantarum DAD-13
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07072871 | Apr 2024 | autoinflammatory syndrome, infectious disease with sepsis | PT Royal Medikalink Pharmalab | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactiplantibacillus plantarum DAD-13 | “A probiotic supplement (Vipilac®) containing Lactiplantibacillus plantarum DAD-13 administered orally via nasogastric tube, 2 capsules daily for 4 days, intended to modulate...” NCT07072871 ↗ |
| Known as | Vipilac | “A probiotic supplement (Vipilac®) containing Lactiplantibacillus plantarum DAD-13 administered orally via nasogastric tube, 2 capsules daily for 4 days, intended to modulate...” NCT07072871 ↗ |
| Modality | Other / unclassified | “The probiotic supplement Lactiplantibacillus plantarum DAD-13 was given in capsule form (2 capsules/day) via NGT for 4 days.” NCT07072871 ↗ |
| Route | Oral | “administered orally via nasogastric tube” NCT07072871 ↗ |